A Phase I Study to Evaluate Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Individuals

NCT05305300 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

135

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19 Pandemic

Interventions

BIOLOGICAL: PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm A
BIOLOGICAL: PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm B

Sponsor

Yisheng Biopharma (Singapore) Pte. Ltd.